Piper Sandler & Co’s Novavax NVAX Stock Holding History

Piper Sandler & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,000	Closed	-$356K	–	136
2014 Q4	$356K	Buy	+3,000	New	+$314K	0.17%	43
2014 Q3	–	Sell	-1,250	Closed	-$116K	–	156
2014 Q2	$116K	Sell	1,250 -2,500	-67%	-$220K	0.08%	85
2014 Q1	$340K	Sell	3,750 -1,138	-23%	-$127K	0.29%	41
2013 Q4	$500K	Buy	+4,888	New	+$345K	0.42%	36

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Piper Sandler & Co's NVAX Position: Q1 2015 in Review

Piper Sandler & Co sold out of Novavax (NVAX) in Q1 2015, closing a stake of 3,000 shares — an estimated $356K sold.

Piper Sandler & Co first reported a position in NVAX in Q4 2013 and held it in 4 quarters. The position peaked at $500K in Q4 2013. 167 funds tracked by Wall St. Rank hold NVAX as of Q1 2015.

Piper Sandler & Co reported no remaining Novavax position as of Q1 2015 after selling out during the quarter.
Piper Sandler & Co sold 3,000 Novavax shares in Q1 2015, an estimated $356K.
Piper Sandler & Co first reported a position in Novavax in Q4 2013 and held it in 4 quarters.
Piper Sandler & Co's Novavax position peaked at $500K in Q4 2013.
167 funds tracked by Wall St. Rank held Novavax as of Q1 2015.

Based on Piper Sandler & Co's 13F filing for Q1 2015, filed 15 May 2015.